In 2013, Themeli et al. reported the first proof-of-concept study showing that the CD19 CAR-engineered iPSCs could be used as a starting cell source for generating the functional CD19 CAR T cells with anti-cancer capability in a xenograft model (56). This evidence concerns the gene CD19 and cancer.